Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Marinus Pharmaceuticals Inc Market Cap
The Marinus Pharmaceuticals Inc (MRNS) share price is expected to increase by 344.45% over the next year. This is based on calculating the average 12-month share price estimate provided by 9 stock analysts who have covered MRNS. Price targets range from $0.3 at the low end to $3 at the high end. The current analyst consensus for MRNS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
MRNS is a stock in Healthcare which has been forecasted to be worth $1.46667 as an average. On the higher end, the forecast price is $3 USD by from Jefferies and on the lower end MRNS is forecasted to be $0.3 by from .
These are the latest 20 analyst ratings of MRNS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Douglas Tsao HC Wainwright & Co. | Neutral | $2 | Reiterates | Nov 14, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $4 | Reiterates | Nov 14, 2024 |
| Jason Kolbert D. Boral Capital | Buy | $3 | Maintains | Nov 13, 2024 |
| Joseph Thome TD Cowen | Hold | Downgrade | Oct 25, 2024 | |
| Brian Abrahams RBC Capital | Sector Perform | $1 | Maintains | Oct 25, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $4 | Maintains | Oct 25, 2024 |
| Andrew Tsai Jefferies | Hold | $0.5 | Downgrade | Oct 25, 2024 |
| Douglas Tsao HC Wainwright & Co. | Neutral | Downgrade | Oct 25, 2024 | |
| Jason Butler JMP Securities | Market Perform | Downgrade | Oct 24, 2024 | |
| Jason Kolbert EF Hutton | Buy | $3 | Maintains | Oct 24, 2024 |
| Jason Kolbert EF Hutton | Buy | $23 | Maintains | Oct 17, 2024 |
| Jason Kolbert EF Hutton | Buy | $23 | Maintains | Oct 11, 2024 |
| Jason Kolbert EF Hutton | Buy | $23 | Initiates | Sep 30, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $13 | Reiterates | Sep 24, 2024 |
| Jason West JMP Securities | Market Outperform | $10 | Reiterates | Sep 23, 2024 |
| Jay Olson Oppenheimer | Outperform | $6 | Upgrade | Sep 23, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $13 | Reiterates | Sep 16, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $13 | Reiterates | Sep 9, 2024 |
| Michael Higgins Ladenburg Thalmann | Neutral | Downgrade | Aug 14, 2024 | |
| Douglas Tsao HC Wainwright & Co. | Buy | $11 | Reiterates | Aug 14, 2024 |
When did it IPO
2014
Staff Count
165
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Scott N. Braunstein M.D.
Market Cap
$17.9M
In 2023, MRNS generated $31.0M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MRNS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Marinus Pharmaceuticals (MRNS) reported Q3 2024 highlights, noting over 200 patients on its ZTALMY therapy and a steady rise in demand. Financial results were also shared.
Why It Matters - Marinus Pharmaceuticals' growth in ZTALMY patient numbers signals strong demand, potentially leading to increased revenues and a positive outlook for future earnings, impacting stock performance.
Tue, 12 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Marinus Pharmaceuticals (MRNS) reported a quarterly loss of $0.42 per share, beating the Zacks Consensus Estimate of $0.44, and improved from a loss of $0.61 per share a year earlier.
Why It Matters - Marinus Pharmaceuticals' smaller-than-expected quarterly loss signals improving financial performance, potentially boosting investor confidence and stock value.
Thu, 24 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Marinus Pharmaceuticals' Phase 3 TrustTSC trial of oral ganaxolone for tuberous sclerosis complex seizures did not meet its primary endpoint, despite some reductions in seizure frequency.
Why It Matters - Marinus Pharmaceuticals’ failure to meet primary endpoints in a key clinical trial could negatively impact stock performance, investor confidence, and future funding opportunities.
Tue, 15 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Marinus Pharmaceuticals has secured a new patent for ZTALMY® (ganaxolone) oral titration regimens targeting various epilepsy disorders, enhancing its intellectual property portfolio.
Why It Matters - The new patent enhances Marinus Pharmaceuticals' market position by protecting its treatment regimen for epilepsy, potentially increasing revenue and investor confidence.
Thu, 17 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Marinus Pharmaceuticals announced new data from the Phase 3 RAISE trial of IV ganaxolone for refractory status epilepticus, meeting one of two co-primary endpoints.
Why It Matters - Positive Phase 3 trial data for Marinus Pharmaceuticals' IV ganaxolone could enhance its market position and attract investor interest, signaling potential revenue growth in treating seizure disorders.
Wed, 16 Oct 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Micro-cap stocks vary widely, including former successful companies aiming for recovery. Investors should assess each firm's potential for resurgence.
Why It Matters - Micro-cap stocks present opportunities for high returns, especially if struggling firms can recover. Investors may find undervalued gems with potential for growth.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
